Rituxan Adds Third NHL Indication In 2006

02 Oct 2006

• By Shirley Haley

The Genentech/Biogen Idec oncologic, first approved in 1997, is now also approved for first-line with CVP and ongoing treatment of stable disease.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

Already a subscriber?